RE: STS Efficacy data within April8 Apr 2023 00:31
100s of trials for cancer. Because cancer is just one single disease. Not a near endless array of varying types of disease defined by often very different characteristics, outcomes and treatments. Hundreds of trials there may be…. How many have low to no side effects at double the dose? We’re targeting a 1.5bn dollar per annum market with AVA6000 in a wider oncology market worth hundreds of billions per annum. The vast array of treatments needed is mind boggling and depressing with it.
On top of the above…. Pages 85 to 86 of the SD presentation that you didn’t look through.
There is huge potential for an improved next generation doxorubicin product considering:
• the market value being generated by current doxorubicin therapies and the expectation that doxorubicin- based therapies will continue to be a key approach for oncology treatment
• there is considerable scope for improvement on the profile of conventional and liposomal doxorubicin, around both safety / tolerability and efficacy
• there is modest future competitor activity exploring new doxorubicin approaches and few products identified to be in direct competition to AVA6000’s approach
So when you say hundreds what you actually mean is almost none.
It’s a real shame when facts smash your FUD right in the face.